10982 results about "Molecular marker" patented technology

Compositions and methods related to transgenic high oleic acid / ALS inhibitor-tolerant soybean plants are provided. Specifically, the present invention provides soybean plants having a DP-305423-1 event which imparts a high oleic acid phenotype and tolerance to at least one ALS-inhibiting herbicide. The soybean plant harboring the DP-305423-1 event comprises genomic / transgene junctions having at least the polynucleotide sequence of SEQ ID NO:8, 9, 14, 15, 20, 21, 83 or 84. The characterization of the genomic insertion site of the DP-305423-1 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean DP-305423-1 events are provided.

The present invention provides a cotton plant event MON 88913 compositions and seed. Also provided are assays for detecting the presence of the cotton plant event MON 88913 based on a DNA sequence and the use of this DNA sequence as a molecular marker in a DNA detection method.

The present invention provides a corn plant designated MON880 7 and DNA compositions contained therein. Also provided are assays for detecting the presence of the corn plant MON88017 based on a DNA sequence and the use of this DNA sequence as a molecular marker in a DNA detection method.

The present invention provides a bentgrass ASR-368 plant and seed. Also provided are assays for detecting the presence of the bentgrass ASR-368 based on a DNA sequence and the use of this DNA sequence as a molecular marker in a DNA detection method.

The invention provides a molecular marker set that can be used for prognosis of colorectal cancer in a colorectal cancer patient. The invention also provides methods and computer systems for evaluating prognosis of colorectal cancer in a colorectal cancer patient based on the molecular marker set. The invention also provides methods and computer systems for determining chemotherapy for a colorectal cancer patient and for enrolling patients in clinical trials.

The present invention provides a cotton plant event MON 88913 compositions and seed. Also provided are assays for detecting the presence of the cotton plant event MON 88913 based on a DNA sequence and the use of this DNA sequence as a molecular marker in a DNA detection method.

Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.

A system and methods for co-registering multi-channel images of a tissue micro array, comprising the steps of, providing a biological material on a substrate; applying one or more molecular probes, adapted to provide fluorescent molecular markers, to the biological material; obtaining a first digital image of the biological material and the fluorescent molecular markers; applying a morphological stain to the biological material; obtaining a second digital image of the biological material, computing information common to the first and second images; and co-registering the second image with the first image based on one or more registration metrics.

The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3′ end. The amplified adapter-ligated restriction fragments are, at least partly, sequenced using high throughput sequencing methods and the sequence parts of the restriction fragments together with the sample-specific identifiers serve as molecular markers.

Disclosed herein are methods and systems for classifying cell labels, for example identifying a signal cell label. In some embodiments, the method comprises: obtaining sequencing data of barcoded targets created using targets in cells barcoded using barcodes, wherein a barcode comprises a cell label and a molecular label. After ranking the cell labels, a minimum of a second derivative plot of a cumulative sum plot can be determined. Using the methods, a cell label can be classified as a signal cell label or a noise cell label based on the number of molecular labels with distinct sequences associated with the cell label and a cell label threshold.

Free-standing microfluidic channels are used to both transport and analyze molecules of interest. In a biochemical context, such molecules may be polypeptides, nucleic acids, or other biomolecules. The free-standing channels provide a real-time readout of concentration without the need for labeling with reporter molecules. The channels can also measure enthalpy values and equilibrium constants by detecting heat released from or absorbed by the sample.

Embodiments are related to the accurate detection of somatic mutations in the plasma (or other samples containing cell-free DNA) of cancer patients and for subjects being screened for cancer. The detection of these molecular markers would be useful for the screening, detection, monitoring, management, and prognostication of cancer patients. For example, a mutational load can be determined from the identified somatic mutations, and the mutational load can be used to screen for any or various types of cancers, where no prior knowledge about a tumor or possible cancer of the subject may be required. Embodiments can be useful for guiding the use of therapies (e.g. targeted therapy, immunotherapy, genome editing, surgery, chemotherapy, embolization therapy, anti-angiogenesis therapy) for cancers. Embodiments are also directed to identifying de novo mutations in a fetus by analyzing a maternal sample having cell-free DNA from the fetus.

The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.

The present invention provides methods for diagnosing, providing a prognosis, and staging thyroid cancer, using panels of molecular markers that are differentially expressed in thyroid cancer. Also provided are methods to identify compounds that are useful for the treatment or prevention of thyroid cancer.

This invention relates to polynucleotide sequences encoding a gene that can confer resistance to at least one herbicide. It further relates to plants and seeds of plants carrying chimeric genes comprising said polynucleotide sequences, which enhance or confer resistance to at least one herbicide, and methods of making said plants and seeds. The invention further presents sequences that can be used as molecular markers that in turn can be used to identify the region of interest in corn lines resulting from new crosses and to quickly and efficiently select the best lines for breeding strategies by avoiding sensitive lines.

Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.

The present invention relates compositions and methods for microRNA expression profiling of cancer stem cells. In particular, the invention relates to a method for identifying and / or diagnosing one or more cancer stem cells, the method comprising identifying from a plurality of nucleic acid molecules, each encoding a microRNA sequence, one or more nucleic acid molecules are differentially expressed in the cancer stem cells and in one or more control cells, wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of cancer stem cells. The invention further relates to a corresponding diagnostic kit of molecular markers, namely the nucleic acid expression signature. Finally, the invention is directed to a method using such nucleic acid expression signatures for preventing the proliferation and / or self-renewal of such cancer stem cells as well as to a corresponding pharmaceutical composition.

The present invention relates to an automatable method for obtaining an improved diagnosis of cancer, and its precancerous stages in uterine cervical smears by simultaneously staining and detecting at least two different molecular markers, which exhibit a disease-associated change in gene expression, in a cell by means of using antibodies or nucleic acid probes.

The use of an imaging system, cell compartment markers, and molecular markers in methods for correlating the movement of molecules within a cell to a particular compartment are provided, including measuring and correlating molecule movement in adherent and non-adherent cells.

The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg / ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker.

The present invention relates to an in vitro method for diagnosing and / or monitoring in a subject a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising detecting and / or analyzing in a test sample derived from the subject one or more mutations at the DNA level in any one or both of the marker genes cKIT (GenBank acc. no. NM_000222.2) and PDGFRA (GenBank acc. no. NM_006206.4), wherein the DNA is circulating DNA, and wherein the presence of any one of the mutations detected in the test sample is indicative of a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor in the subject. The present invention is also directed to a corresponding kit-of-parts for diagnosing and / or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor, comprising means for detecting and / or analyzing one or more mutations as defined herein, as well as to the use of one or more mutations as defined herein as a panel of molecular markers for diagnosing and / or monitoring a gastrointestinal stromal tumor or a predisposition to develop a gastrointestinal stromal tumor.

The invention belongs to the technical field of computer-aided diagnosis, and specifically relates to a brain glioma molecular marker nondestructive prediction method and a prediction system based on radiomics. The method comprises the following steps: adopting a three-dimensional magnetic resonance image automatic segmentation method based on a convolution neural network; registering a tumor obtained from segmentation to a standard brain atlas, and acquiring 116 position features of tumor distribution; getting 21 gray features, 15 shape features and 39 texture features through calculation; carrying out three-dimensional wavelet decomposition on the gray features and the texture features to get 480 wavelet features of eight sub-bands; acquiring 671 high-throughput features from the three-dimensional T2-Flair magnetic resonance image of each case; using a feature screening strategy combining p-value screening and a genetic algorithm to get 110 features highly associated with IDH1; and using a support vector machine and an AdaBoost classifier to get a classification of which the IDH1 prediction accuracy is 80%. As a novel method of radiomics, the method provides a nondestructive prediction scheme of important molecular markers for clinical diagnosis of gliomas.

The invention provides a NP chip used for identifying rice variety. The chip comprises 3072 molecular markers, and the 3072 molecular markers are shown in SEQ ID NO. 0001- SEQ ID NO. 3072. The invention also provides a preparation method for the above SNP chip, and the preparation method comprises the steps: acquiring the SNP molecular markers from rice cultivar resequencing data, screening the SNP molecular markers and employing the screened molecular markers to design a probe and prepare the SNP chip. The invention also provides application of the above SNP chip to rice variety authenticity and identity identification. The provided application of the combination of the 3072 SNP molecular markers helps to greatly improve the detection accuracy, shorten the detection time and substantially improve our country identification technology level on rice variety.

The invention provides a major SNP (single nucleotide polymorphism) marker influencing the growth traits of pigs. The SNP marker is located at a nucleotide sequence of an HMGA1 gene of a pig chromosome 7, a locus of the SNP marker is the nucleotide mutation of C857-G857 with an SEQ ID NO:1 sequence labeling position of 857, corresponding to a 34983991st nucleotide locus C> on chromosome 7 in a reference sequence in an international pig genome version 10.2, G mutation, or one of seven other loci completely linked with the locus. The invention also provides the application of the SNP marker in the genetic improvement of growth traits of breeding pigs, and provides the application of an SNP molecular marker with a linkage disequilibrium degree (r2) with the SNP marker of greater than 0.8 in the genetic improvement of growth traits of breeding pigs. The growth traits include one or more of the length and height of a living body of a pig, carcass length, carcass weight, daily gain and head weight. According to the invention, the breeding process of breeding pigs can be accelerated, the productivity of breeding pigs can be effectively improved, and remarkable economic benefits can be obtained.

The invention relates to application of a long-chain non-coding RNA as a blood molecular marker for disease diagnosis. Specifically, the inventor successfully isolates and detects a long-chain non-coding RNA (lncRNA) in blood of human or non-human mammal; the long-chain non-coding RNA in blood of human or non-human mammal stably exists in form of fragments with different expressive abundance; a short-chain RNA (named as MD miniRNA)from lncRNA MALAT-1 in blood is from prostate cancer (PCa) cells, and releases into blood; PCa cells cultured in vitro can secrete MD-miniRNA and release into a nutrient solution; and high expression of MD-miniRNA can be detected in transplanted tumor mice plasma. In addition, expression of MD-miniRNA is in positive correlation with morbidity of PCa, and the MD-miniRNA realizes sensitivity higher than 40% and specificity higher than 80% in distinguishing prostate puncture positive and negative patients. Therefore, the MD-miniRNA is a novel cancer (especially prostate cancer) blood molecular diagnostic marker, and can significantly improve the accuracy of diagnosis.

This disclosure concerns a plant of the genus, Brassica, or parts thereof, which comprise one or more traits selected from the group consisting of high oleic acid content, low linolenic acid content, increased herbicide resistance, restorer of cytoplasmic male sterility, and increased clubroot disease (Plasmodiophora brassicae) resistance, compared to a wild-type plant of the same species. This disclosure further relates to wild-type and mutant alleles of genes involved in these traits, molecular markers linked thereto, and methods of their use.

Drug-naive and drug-free schizophrenic PBL were screened to identify additional markers that are differentially expressed compared to healthy individuals using microarray and quantitative real-time PCR (QRT-PCR) techniques. Genes for dopamine D2 receptor (DRD2) and inwardly rectifying potassium channel (Kir2.3) were found to be overexpressed in microarray analysis. Increased mRNA levels were confirmed by QRT-PCR using SybrGreen method and dual labeled TaqMan probes.The invention relates to a method for diagnosing schizophrenia in a subject comprising assessing the level or the expression level of at least one of the following genes or proteins: Kir2.3 or DRD2 or a gene encoding Kir2.3 or DRD2. The invention further relates to agents and uses thereof, said agents specifically binding to said proteins or nucleic acids encoding them, diagnostic kits and screening methods.Use of both molecular markers allow prediction of schizophrenia and help to follow efficiency of drugs in therapy in order to provide a more tailored medication for schizophrenic patients.

The invention provides a kit for separating genome DNA by using magnetic balls and application thereof. The kit comprises magnetic balls, a magnetic frame, a genome DNA extraction reagent (lysing solution, binding solution, rinsing solution A, rinsing solution B and eluent) and specifications; the main steps of extracting the gene DNA comprise cell lysis, nucleic acid absorption, impurity removing and nucleic acid elution. The application of the kit for extracting the genome DNA does not need to use large-toxicity organic solvents of phenol, chloroform and the like, has good safety, and simple, fast and time-saving operation, and simultaneously can extract a plurality of samples. The kit can extract the genome DNA from materials of animals, plants, bacteria, fungus, blood, virus, animal source feed stuff, samples in the forensic medicine and the like, the DNA has high yield and purity, and the obtained genome DNA can be used for experiments such as PCR amplification, gene cloning, construction of genomic library, sequence measurement, molecular hybridization, molecular marking and the like. The kit can be stored at the temperature of 4 DEG C, also can be placed at room temperature, and is convenient to transport.